Group 1 - Humana shares increased by 4% to close at $256.62, following a significant trading volume, despite a 20.9% loss over the past four weeks [1] - The rise in Humana's stock price is attributed to improvements in its Medicare star ratings, with approximately 20% of its members (around 1.2 million individuals) enrolled in plans rated 4 stars or higher for 2026 [2] - The proportion of members in 4.5-star plans increased significantly from 3% in 2025 to 14% for 2026, indicating enhanced service quality [2] Group 2 - Humana's Medicare plans are characterized by their breadth, flexibility, and competitive positioning, offering a variety of Medicare Advantage, Prescription Drug, and Supplement plans supported by a robust provider network [3] - The company is expected to report quarterly earnings of $2.88 per share, reflecting a year-over-year decline of 30.8%, while revenues are projected to be $31.92 billion, a 9% increase from the previous year [4] - The consensus EPS estimate for Humana has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [5] Group 3 - Humana holds a Zacks Rank of 3 (Hold) within the Zacks Medical - HMOs industry, which includes Cigna, another company in the same sector that saw a 1.8% increase in its stock price [6] - Cigna's consensus EPS estimate for its upcoming report has changed by -0.1% to $7.7, representing a 2.5% increase from the previous year [7]